Business
Annual Report for the Year Ended 31 December 2022
Annual Report for the Year Ended 31 December 2022.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n23 May 2023\nOndine Biomedical Inc.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\nAnnual Report for the Year Ended 31 December 2022\nOndine Biomedical (AIM: OBI) announces that its Annual Report for the year ended 31 December 2022 was posted on 23 May 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/\n \n\n\n\n\nOndine Biomedical Inc. \n\n\n \n\n\n\n\nAngelika Vance, Corporate Communications\n\n\n+001 (1) 604 838 2702\n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser and Joint Broker)\n\n\n \n\n\n\n\nAubrey Powell, Asha Chotai, Sam Butcher \n\n\n+44 (0)20 7496 3000\n\n\n\n\n \n\n\n \n\n\n\n\nRBC Capital Markets (Joint Broker)\n\n\n \n\n\n\n\nRupert Walford, Kathryn Deegan\n\n\n+44 (0) 20 7653 4000\n\n\n\n\n \n\n\n \n\n\n\n\nVane Percy & Roberts (Media Contact)\n\n\n \n\n\n\n\nSimon Vane Percy, Amanda Bernard\n\n\n+44 (0) 77 1000 5910\n\n\n\n\n \nAbout Ondine Biomedical Inc.\nOndine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.\n \n\n","length":4577,"tagName":"div"}]